Primary study · included by 2 reviews

Endothelial Dysfunction Marker Variation in Young Adults with Chronic Apical Periodontitis before and after Endodontic Treatment.

Bergandi 2019 · Bergandi Loredana, Giuggia Beatrice, Alovisi Mario, et al. · Journal of endodontics · 2019

Included by

Impact of Endodontic Treatment of Teeth With Apical Periodontitis on Levels of Inflammatory Biomarkers Associated With Cardiovascular Risk: A Systematic Review and Meta-Analysis.

Non-Cochrane · intervention · 2026 · cited as Bergandi 2019 · Table 1; References

The review does not say which of its outcomes this study informs.

Does endodontic treatment modify serum inflammatory markers of cardiovascular risk in individuals with asymptomatic apical periodontitis? a systematic review and meta-analysis.

Non-Cochrane · intervention · 2026 · cited as Bergandi 2019 · Table 1; Figs. 2-4; reference list

Outcome this study informs	Pooled effect	Evidence	Certainty
Serum interleukin-6 (IL-6) Endodontic treatment (non-surgical treatment or retreatment, with or without surgery) vs Internal control group (healthy individuals; own-control analysis) · Post-treatment (follow-up 7 days to 12 months)	MD 0.81 [-0.27, 1.90]	3 studies	GRADE not reported
Serum tumor necrosis factor-alpha (TNF-alpha) Endodontic treatment (non-surgical treatment or retreatment, with or without surgery) vs Internal control group (healthy individuals; own-control analysis) · Baseline (before treatment)	MD 2.19 [0.61, 3.76]	3 studies	GRADE not reported
Serum ICAM-1 Endodontic treatment (non-surgical treatment or retreatment, with or without surgery) vs Internal control group (healthy individuals; own-control analysis) · Post-treatment (follow-up 7 days to 12 months)	MD 32.15 [9.32, 54.99]	2 studies	GRADE not reported
Serum interleukin-6 (IL-6) Endodontic treatment (non-surgical treatment or retreatment, with or without surgery) vs Internal control group (healthy individuals; own-control analysis) · Baseline (before treatment)	MD 1.55 [0.89, 2.21]	1 study	GRADE not reported
Serum interleukin-6 (IL-6) Endodontic treatment (non-surgical treatment or retreatment, with or without surgery) vs Internal control group (healthy individuals; own-control analysis) · Post-treatment (follow-up 7 days to 12 months)	MD 1.49 [0.82, 2.16]	1 study	GRADE not reported
Serum interleukin-6 (IL-6) Endodontic treatment (non-surgical treatment or retreatment, with or without surgery) vs Internal control group (healthy individuals; own-control analysis) · Baseline (before treatment)	MD 0.45 [-1.07, 1.97]	2 studies	GRADE not reported
Serum VCAM-1 Endodontic treatment (non-surgical treatment or retreatment, with or without surgery) vs Internal control group (healthy individuals; own-control analysis) · Baseline (before treatment)	MD 0.00 [-0.01, 0.02]	2 studies	GRADE not reported
Serum tumor necrosis factor-alpha (TNF-alpha) Endodontic treatment (non-surgical treatment or retreatment, with or without surgery) vs Internal control group (healthy individuals; own-control analysis) · Baseline (before treatment)	MD 4.26 [3.02, 5.50]	1 study	GRADE not reported
Serum interleukin-6 (IL-6) Endodontic treatment (non-surgical treatment or retreatment, with or without surgery) vs Internal control group (healthy individuals; own-control analysis) · Post-treatment (follow-up 7 days to 12 months)	MD -0.04 [-1.46, 1.39]	2 studies	GRADE not reported
Serum ICAM-1 Endodontic treatment (non-surgical treatment or retreatment, with or without surgery) vs Internal control group (healthy individuals; own-control analysis) · Baseline (before treatment)	MD 86.49 [63.54, 109.44]	2 studies	GRADE not reported
Serum tumor necrosis factor-alpha (TNF-alpha) Endodontic treatment (non-surgical treatment or retreatment, with or without surgery) vs Internal control group (healthy individuals; own-control analysis) · Post-treatment (follow-up 7 days to 12 months)	MD -0.25 [-0.60, 0.10]	2 studies	GRADE not reported
Serum tumor necrosis factor-alpha (TNF-alpha) Endodontic treatment (non-surgical treatment or retreatment, with or without surgery) vs Internal control group (healthy individuals; own-control analysis) · Baseline (before treatment)	MD 0.11 [-0.74, 0.97]	2 studies	GRADE not reported
Serum tumor necrosis factor-alpha (TNF-alpha) Endodontic treatment (non-surgical treatment or retreatment, with or without surgery) vs Internal control group (healthy individuals; own-control analysis) · Post-treatment (follow-up 7 days to 12 months)	MD 4.90 [3.60, 6.20]	1 study	GRADE not reported
Serum VCAM-1 Endodontic treatment (non-surgical treatment or retreatment, with or without surgery) vs Internal control group (healthy individuals; own-control analysis) · Post-treatment (follow-up 7 days to 12 months)	MD 0.00 [-0.00, 0.01]	2 studies	GRADE not reported
Serum interleukin-6 (IL-6) Endodontic treatment (non-surgical treatment or retreatment, with or without surgery) vs Internal control group (healthy individuals; own-control analysis) · Baseline (before treatment)	MD 1.01 [0.10, 1.93]	3 studies	GRADE not reported
Serum tumor necrosis factor-alpha (TNF-alpha) Endodontic treatment (non-surgical treatment or retreatment, with or without surgery) vs Internal control group (healthy individuals; own-control analysis) · Post-treatment (follow-up 7 days to 12 months)	MD 1.04 [-0.38, 2.46]	3 studies	GRADE not reported

2 including reviews in total.